論文 - 詳細
| RRC ID | 64024 |
|---|---|
| 著者 | Koga K, Aoki M, Sameshima T, Hamasaki M, Egawa N, Seiki M, Toole BP, Suzumiya J, Nabeshima K. |
| タイトル | Synthetic emmprin peptides inhibit tumor cell-fibroblast interaction-stimulated upregulation of MMP-2 and tumor cell invasion. |
| ジャーナル | Int J Oncol |
| Abstract |
Stromal cells are the main source of matrix metalloproteinases (MMPs) in human carcinoma tissues. Emmprin is a glycosylated transmembrane protein containing two immunoglobulin (Ig) domains that is expressed in carcinoma cells and stimulates MMP production by adjacent stromal cells. The first Ig domain (ECI) of emmprin contains the biologically active site. We investigated whether synthetic peptides carrying a partial ECI sequence could inhibit emmprin activity. Only the second peptide (emp#2), which contains a putative N-glycosylation site sequence, inhibited emmprin-stimulated production of MMP-2 in co-cultures of fibroblasts and several different human tumor cells types, including carcinoma, sarcoma, melanoma, leukemia and glioma cells. Moreover, emp#2 significantly inhibited the invasive activity of glioblastoma cells promoted by interaction with fibroblasts. Perturbation of emmprin activity by this peptide may have potential therapeutic uses in the prevention of MMP-2-dependent cancer invasion. |
| 巻・号 | 39(3) |
| ページ | 657-64 |
| 公開日 | 2011-9-1 |
| DOI | 10.3892/ijo.2011.1060 |
| PMID | 21637915 |
| MeSH | Amino Acid Sequence Basigin / chemistry Basigin / metabolism Basigin / pharmacology* Cell Communication / drug effects* Cell Line, Tumor Coculture Techniques Fibroblasts / enzymology Fibroblasts / pathology* Glioblastoma / enzymology Glioblastoma / genetics Glioblastoma / pathology HEK293 Cells Humans Matrix Metalloproteinase 2 / biosynthesis* Matrix Metalloproteinase 2 / genetics Matrix Metalloproteinase 2 / metabolism Molecular Sequence Data Neoplasm Invasiveness Neoplasms / enzymology Neoplasms / genetics Neoplasms / pathology* Peptide Fragments / chemistry Peptide Fragments / pharmacology* Up-Regulation / drug effects |
| IF | 3.899 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 6 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | U251(RCB0461) |